Bristol-Myers Squibb logo

Bristol-Myers SquibbNYSE: BMY

Profile

Sector:

Healthcare

Country:

United States

IPO:

01 June 1972

Next earnings report:

06 February 2025

Last dividends:

04 October 2024

Next dividends:

N/A
$119.40 B
-30%vs. 3y high
99%vs. sector
-vs. 3y high
-vs. sector
-1%vs. 3y high
87%vs. sector
-31%vs. 3y high
43%vs. sector

Price

after hours | Sat, 23 Nov 2024 00:59:26 GMT
$58.87+$0.65(+1.12%)
$11.89 B$11.54 B
$11.89 B$1.21 B

Analysts recommendations

Institutional Ownership

BMY Latest News

Bristol-Myers Squibb Company (BMY) Jefferies London Healthcare Conference (Transcript)
seekingalpha.com19 November 2024 Sentiment: NEUTRAL

Bristol-Myers Squibb Company (NYSE:BMY) will be participating in the Jefferies London Healthcare Conference on November 19, 2024, at 4:30 AM ET. The company representatives include David Elkins, the CFO, along with another unidentified representative. Thank you all for joining us for this next discussion.

Bristol-Myers Squibb: Buy This Bargain Before It's Gone
seekingalpha.com17 November 2024 Sentiment: POSITIVE

Bristol-Myers Squibb's stock has increased by over 25% in the last six months, showing strong advancements in its oncology and neuroscience divisions. In the third quarter of 2024, Yervoy's sales reached $642 million, which is a 10.9% rise compared to the same time last year and a 1.9% increase from the previous quarter. Additionally, on September 26, 2024, the company revealed the long-anticipated approval of Cobenfy for treating schizophrenia.

6 of Wall Street's Most Beloved High-Yield Stocks Are On Sale
247wallst.com17 November 2024 Sentiment: POSITIVE

Yields have gradually increased since the Federal Reserve lowered interest rates in September.

Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer
businesswire.com15 November 2024 Sentiment: POSITIVE

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CHMP--Bristol Myers Squibb has received a favorable opinion from the CHMP for the use of Opdivo® in combination with Yervoy® as a first-line treatment for adult patients with microsatellite instability.

Bristol Myers faces renewed, $6.7 bln lawsuit over delayed cancer drug
reuters.com14 November 2024 Sentiment: NEGATIVE

On Thursday, Bristol Myers Squibb faced a $6.7 billion lawsuit that accuses the company of deceiving former Celgene shareholders by postponing federal approval for three drugs. This lawsuit comes just a month and a half after a federal judge unexpectedly threw out an earlier version of the case.

Bristol-Myers Squibb Company (BMY) Guggenheim Securities Inaugural Healthcare Innovation Conference (Transcript)
seekingalpha.com11 November 2024 Sentiment: POSITIVE

Bristol-Myers Squibb Company (NYSE:BMY) will participate in the Guggenheim Securities Inaugural Healthcare Innovation Conference on November 11, 2024, at 10:00 AM ET. The company will be represented by Samit Hirawat, the Executive Vice President and Chief Medical Officer, and Robert Plenge, the Executive Vice President and Chief Research Officer. Seamus Fernandez from Guggenheim will also be part of the conference call.

Bristol Myers Stock Trading Near 52-Week High: Time to Buy or Sell?
zacks.com11 November 2024 Sentiment: POSITIVE

BMY has performed well over the last three months. Recently, the stock reached its highest point in a year.

Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
benzinga.com08 November 2024 Sentiment: POSITIVE

In the third quarter of 2024, the biopharmaceutical industry began to recover, driven by growing investor confidence after the U.S. Federal Reserve lowered interest rates in September.

What's Next For BMY Stock After An Upbeat Q3?
forbes.com07 November 2024 Sentiment: POSITIVE

Bristol Myers Squibb (NYSE: BMY) has just announced its Q3 results, showing that both revenue and earnings were higher than expected. The company reported revenue of $11.9 billion and adjusted earnings of $1.80 per share, while analysts had predicted $11.3 billion and $1.49.

Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
zacks.com06 November 2024 Sentiment: POSITIVE

Users of Zacks.com have been paying a lot of attention to Bristol Myers (BMY) lately. Therefore, it's important to understand the key factors that could influence the stock's future.

What type of business is Bristol-Myers Squibb?

Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development, licensing, manufacturing, marketing, and sale of biopharmaceutical products. Bristol-Myers pharmaceutical products are chemically synthesized or low molecular weight drugs for the following therapeutic areas: oncology; immunology with priorities in psoriasis, lupus, cancer, inflammatory bowel diseases, HIV; cardiovascular with priority in heart disease; fibrotic diseases of the lungs and liver; hepatitis B, C. The line of pharmaceuticals is represented by 10 trade brands. The Bristol-Myers company was registered in 1933 and essentially is the successor of a New York pharmaceutical manufacturer that has been in operation since 1887. Bristol-Myers' major manufacturing facilities are located in the United States, Puerto Rico, Ireland, France, and Italy.

What sector is Bristol-Myers Squibb in?

Bristol-Myers Squibb is in the Healthcare sector

What industry is Bristol-Myers Squibb in?

Bristol-Myers Squibb is in the Drug Manufacturers - General industry

What country is Bristol-Myers Squibb from?

Bristol-Myers Squibb is headquartered in United States

When did Bristol-Myers Squibb go public?

Bristol-Myers Squibb initial public offering (IPO) was on 01 June 1972

What is Bristol-Myers Squibb website?

https://www.bms.com

Is Bristol-Myers Squibb in the S&P 500?

Yes, Bristol-Myers Squibb is included in the S&P 500 index

Is Bristol-Myers Squibb in the NASDAQ 100?

No, Bristol-Myers Squibb is not included in the NASDAQ 100 index

Is Bristol-Myers Squibb in the Dow Jones?

No, Bristol-Myers Squibb is not included in the Dow Jones index

When was Bristol-Myers Squibb the previous earnings report?

No data

When does Bristol-Myers Squibb earnings report?

The next expected earnings date for Bristol-Myers Squibb is 06 February 2025